Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the long-term safety and tolerability of inhaled antifibrotic medications, specifically AP01, in participants who have previously completed Avalyn Pharma sponsored studies involving this treatment. The study focuses on individuals with progressive pulmonary fibrosis or idiopathic pulmonary fibrosis IPF, excluding IPF subjects from the US and Canada. The goal is to continue assessing the effects of AP01 over an extended period. Participants will receive 100 mg of inhaled pirfenidone solution AP01 twice daily using the eFlow Nebulizer System. The study includes a ScreeningBaseline Visit, an open-label Treatment Period where all participants receive AP01, and a Follow-upEnd of Study phone call approximately two weeks after the last dose. The dosing during the treatment period will be monitored with a paper diary and by collecting any unused medication. Throughout the study, participants will be assessed for long-term safety and tolerability outcomes, including changes in lung function measured by forced vital capacity FVC, disease stabilization, and quality of life. The trial is expected to last an average of six years, with evaluations continuing until the studys end. Participants will have regular monitoring and follow-up to track their progress and adherence to the treatment.